Pediatrix Medical Group (NYSE:MD) Upgraded to “Buy” by Jefferies Financial Group

Jefferies Financial Group upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research report released on Thursday morning, Marketbeat reports. The brokerage currently has $14.00 target price on the stock, up from their prior target price of $8.00.

MD has been the subject of several other reports. UBS Group upped their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a neutral rating in a report on Friday, August 9th. StockNews.com raised shares of Pediatrix Medical Group from a sell rating to a hold rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised Pediatrix Medical Group from a sell rating to a hold rating and set a $8.00 price objective on the stock in a research report on Friday, June 7th. Finally, Truist Financial increased their target price on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a hold rating in a research report on Thursday, August 15th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average target price of $10.30.

Pediatrix Medical Group Stock Down 0.9 %

Shares of NYSE:MD opened at $11.26 on Thursday. The stock’s 50-day moving average is $10.04 and its 200 day moving average is $8.88. The company has a market cap of $966.90 million, a PE ratio of -13.25, a P/E/G ratio of 1.64 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $13.01.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The firm had revenue of $504.30 million for the quarter, compared to analysts’ expectations of $505.49 million. During the same period in the previous year, the firm earned $0.37 earnings per share. The business’s revenue was up .7% compared to the same quarter last year. Sell-side analysts anticipate that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Buying and Selling

In related news, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares in the company, valued at approximately $1,943,272.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO C Marc Richards sold 32,562 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares of the company’s stock, valued at approximately $1,943,272.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The disclosure for this sale can be found here. Insiders have sold 68,100 shares of company stock valued at $701,889 over the last quarter. Corporate insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC purchased a new stake in shares of Pediatrix Medical Group during the second quarter valued at $175,000. Dana Investment Advisors Inc. lifted its stake in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Pediatrix Medical Group by 663.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 28,260 shares of the company’s stock valued at $213,000 after acquiring an additional 24,560 shares during the last quarter. Brandes Investment Partners LP grew its stake in shares of Pediatrix Medical Group by 12.8% in the second quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock worth $5,438,000 after acquiring an additional 83,588 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock valued at $245,000 after purchasing an additional 1,088 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.